Medication info
Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg

Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletEmpagliflozin Amorphous›10mg / 1 tablet
Manufacturer / importer
Aprogen Biosystems, Co., Ltd.
Appearance
Yellow, oblong, extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501135 · Approved 2025.05.09 · Insurance code 645211080

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, this drug may be administered as 1 tablet once daily with a meal to patients receiving empagliflozin 10 mg and metformin hydrochloride (extended-release) 1000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredient. If the patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is adequately controlled (see Precautions for Use, section 5, General Precautions). ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their previous doses of empagliflozin and metformin. When converting from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, sections 4, Adverse Reactions, and 6, Interactions). Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly patients In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Aprogen Biosystems, Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This drug is used to help control blood sugar in adults with type 2 diabetes who are following a diet and exercise regimen. It is particularly used in adults with type 2 diabetes who do not achieve sufficient blood sugar control and have cardiovascular disease; the impact on the occurrence of cardiovascular events should be considered according to expert guidelines. Therefore, this drug helps improve blood sugar management and is included in an appropriate treatment plan to enhance the patient's health.

How to take

Adult dose

For antidiabetic therapy, this drug may be administered as 1 tablet once daily with a meal to patients receiving empagliflozin 10 mg and metformin hydrochloride (extended-release) 1000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily in the evening with a meal. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredient. If the patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is adequately controlled (see Precautions for Use, section 5, General Precautions). ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their previous doses of empagliflozin and metformin. When converting from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, sections 4, Adverse Reactions, and 6, Interactions). Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly patients In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This drug helps to control blood sugar levels. However, there are several precautions to be aware of when taking this medication. Firstly, one of the main ingredients, metformin, can rarely cause a serious condition known as lactic acidosis. Lactic acidosis is a condition that occurs when lactic acid builds up excessively in the body, which can be life-threatening if not treated. Additionally, taking this drug along with other diabetes medications such as insulin or sulfonylureas can increase the risk of hypoglycemia. This medication is not to be administered to patients with significantly impaired kidney function, acute infections, heart problems, or liver dysfunction. It is especially safe to avoid use in patients with moderate to severe kidney dysfunction. Patients scheduled for surgery or those undergoing tests that use iodine-based contrast agents should temporarily discontinue taking this medication. This drug may reduce the body's fluid levels, so extra caution should be taken in cases of dehydration, diarrhea, or vomiting, and it should be used carefully in elderly patients or those at risk of decreased fluid volume. During treatment, it is important to regularly monitor not only blood sugar but also kidney function. Also, vitamin B12 levels may decrease, so blood tests should be conducted if necessary. This drug may increase the risk of genital infections and urinary tract infections; consult a doctor immediately if related symptoms occur. Women who are pregnant, may become pregnant, or are breastfeeding are advised not to use this medication. Overdosage may lead to serious side effects, so if more than the prescribed amount is taken, seek medical attention right away. Lastly, this drug should be swallowed whole without crushing, chewing, or breaking the tablet, and it's normal for the tablet coating to appear in the stool. By following these precautions carefully, this medication can help with blood sugar control.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • reduced fluid volume
Show 107 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • reduced glomerular filtration rate
  • vomiting
  • diarrhea
  • gastrointestinal disturbances
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • tendonitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • necrosis of the perineum
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic bleeding
  • soft tissue infection
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pneumonia
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • cerebral aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • ureterolithiasis
  • hematuria
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension
  • insomnia
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to protect it from air or moisture and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Yellow, oblong, extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.